Skip to main content
Premium Trial:

Request an Annual Quote

Incyte s Q4 Revenues Jump, while Losses Widen: $240M Revenues Expected for 2001

NEW YORK, Feb 1 – Bolstered by solid revenues on its custom genomics programs, Incyte posted increased fourth quarter revenues Thursday, and forecasted a continuing growth curve throughout 2001.

Incyte expects to post revenues of between $220 and $240 million in the coming year, said John Vuko, Incyte’s Chief Financial officer.

Separately, the company also reiterated its confidence that a judge had ruled favorably in a January 22 patent litigation hearing with Affymetrix. Lee Bendekegey, the company’s general counsel, said he was confident the ruling set up Incyte to file for summary judgment, a motion that would have Affymetrix’s claims dismissed without trial.

Incyte’s revenue for the fourth quarter increased 20 percent to $55.4 million, versus $46.0 million for the year-ago quarter. These included database and partnership revenues of $40.6 million, compared with $30.6 million in the same period of 1999, and custom genomics revenues of $14.8 million, or 48 percent greater than the $10 million in revenue posted for the same quarter last year.

“The Internet has been a major driving force for the growth in the custom genomics area," Incyte CEO Roy Whitfield said, referring to Incyte’s Web-based e-commerce site that allows medical researchers to purchase information on Incyte’s library of full length genes. “We would expect custom genomics to [continue to] outpace general development in the coming quarter."

Incyte posted net losses of $7.4 million for the quarter, meeting Wall Street’s expectations of 11 cents per share, according to a poll of 10 brokers conducted by FirstCall/Thomson financial. These losses widened slightly compared to the 1999 fourth quarter losses of $6.4 million.

During the fourth quarter, the company continued to sink significant investments into R&D, spending $53.9 million for the quarter, compared to $42.6 million for the same period in 1999. The company’s sales and administrative expenses also surged to $18.5 million from $10.3 million for the year-ago quarter.

In the last year, said Whitfield, “Incyte’s direct sales and marketing organization has grown from a ten-person group located exclusively in Palo Alto to a 100 person global initiative.”

The company will continue to invest significantly in these areas during the coming year, Whitfield said. Incyte


ill spend $60 million on “further development of Incyte's intellectual property portfolio and internal disease pathway and therapeutic drug discovery programs."

For 2001, the company’s most important goal is the hiring of a new president. Other priorities include partnerships with pharma in selected therapeutic areas, and collaboration with an antibody development company, said Whitfield.

The Scan

Interfering With Invasive Mussels

The Chicago Tribune reports that researchers are studying whether RNA interference- or CRISPR-based approaches can combat invasive freshwater mussels.

Participation Analysis

A new study finds that women tend to participate less at scientific meetings but that some changes can lead to increased involvement, the Guardian reports.

Right Whales' Decline

A research study plans to use genetic analysis to gain insight into population decline among North American right whales, according to CBC.

Science Papers Tie Rare Mutations to Short Stature, Immunodeficiency; Present Single-Cell Transcriptomics Map

In Science this week: pair of mutations in one gene uncovered in brothers with short stature and immunodeficiency, and more.